Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology.[1]
The study’s authors tracked nearly 23,000 TMVr hospitalizations. All patients were treated with Abbott’s MitraClip device in the United States from 2014 to 2018, and 3.4% presented with a history of malignancy.
“Although previous studies have described the use of transcatheter aortic valve replacement in patients with malignancy, there is a paucity of data investigating outcomes of TMVr in patients with a history of cancer,” wrote first author Agam Bansal, MD, an internal medicine specialist with Cleveland Clinic, and colleagues.
Overall, patients with cancer were slightly younger and more likely to be male. Patients with cancer and without cancer had similar rates of in-hospital mortality, acute kidney injury and acute myocardial infarction after TMVr with the MitraClip device. However, patients with cancer did have higher rates of 30-day hospital readmissions (17.4% vs. 14.1%), 30-day heart failure hospitalizations (15.2% vs. 11.6%) and required blood transfusions (11.3% vs. 6.9%).
These higher 30-day readmission rates “must be weighed in the decision to pursue MitraClip,” the team wrote, “although the degree of clinical significance … is likely marginal.”
“Although current guidelines recommend MitraClip in patients with a life expectancy greater than one year, it is difficult to estimate survival especially in patients with cancer,” Bansal et al. wrote. “Additionally, symptomatic mitral regurgitation (MR) may be a rate-limiting factor in optimally managing cancers, and therefore, performing MitraClip tenably serves as a viable option to improve the functional status of patients with cancer and ultimately offer them life-prolonging cancer treatment modalities. As such, multidisciplinary decision-making by cardiologists and oncologists is warranted to evaluate the need for MitraClip in patients with cancer.”
One key limitation of this analysis was its retrospective, observational design, the group wrote. They also lacked certain data typically found on echocardiographs, including each patient’s MR grade and ejection fraction.
The team concluded with a look to the future, noting that much more research is still needed.
“We reveal promising short-term MitraClip outcomes in patients with a history of malignancy; yet future studies are needed to elucidate the impact of varying types, stages, and treatments of cancer on long-term outcomes in patients with an indication for TMVr,” they wrote.
Related Structural Heart Disease Content:
TAVR vs. surgery among children and young adults with congenital heart disease
VIDEO: Creating an integrated heart team program in central Texas
Mitral annulus calcification more than doubles a patient’s risk of heart valve disease
Reference:
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.